Related Experiment Videos
Severe myocarditis following high-dose interleukin-2 administration.
W E Samlowski1, J H Ward, C M Craven
1Salt Lake City Veterans Administration Medical Center, UT.
Archives of Pathology & Laboratory Medicine
|August 1, 1989
Summary
High-dose interleukin-2 (IL-2) therapy for renal cell carcinoma can cause severe heart dysfunction. This case confirms IL-2-induced myocarditis, a rare but serious side effect.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- High-dose interleukin-2 (IL-2) is used for renal cell carcinoma treatment.
- IL-2 immunotherapy can have significant systemic side effects.
Observation:
- A patient receiving high-dose IL-2 developed severe myocardial dysfunction.
- Echocardiography showed anteroseptal hypokinesis, mimicking myocardial infarction.
Findings:
- Postmortem examination revealed diffuse lymphocytic and eosinophilic myocarditis with myocyte necrosis.
- This is the first confirmed case of IL-2-associated myocarditis.
Implications:
- IL-2 therapy requires careful cardiac monitoring.
- Understanding IL-2's cardiotoxicity is crucial for patient safety and treatment protocols.